Selamat Ginting, C. Ginting, O. Yulizal, Jekson M. Siahaan
2025.10.17African Journal of Infectious Diseases
tlooto Summary
Findings support the potential of DIF as a complementary therapeutic approach for T2DM, although further research is needed to determine the optimal fasting regimen and its applicability in humans.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, oxidative stress, and systemic inflammation. Diurnal intermittent fasting (DIF), a fasting pattern synchronized with circadian rhythms, has been proposed as a potential strategy to alleviate metabolic disturbances, but evidence from controlled animal studies remains limited. Materials and Methods: This experimental study employed a post-test-only control group design using thirty-six male Wistar rats. T2DM was induced by streptozotocin (65 mg/kg) and nicotinamide (230 mg/kg). Animals were randomized into four groups: diabetic control (G1), and three DIF-treated groups fasting two (G2), three (G3), and six (G4) days per week. Blood glucose was measured weekly. On day 28, serum levels of superoxide dismutase (SOD) and interleukin-6 (IL-6) were analyzed using enzyme-linked immunosorbent assay (ELISA). Results: DIF significantly reduced blood glucose levels in all intervention groups compared to the control (p < 0.05). The G4 group showed the highest SOD activity and the greatest IL-6 reduction (p < 0.05). However, there was no significant glucose difference between G3 and G4, suggesting a plateau in glycemic improvement. Conclusion: DIF improves glycemic control, enhances antioxidant defense through increased SOD activity, and reduces systemic inflammation via IL-6 suppression in a T2DM rat model. These findings support the potential of DIF as a complementary therapeutic approach for T2DM, although further research is needed to determine the optimal fasting regimen and its applicability in humans.
Citation format
GINTING, Selamat, et al. EFFECT OF DIURNAL INTERMITTENT FASTING (DIF) ON ANTIOXIDANT AND PRO INFLAMMATORY MEDIATORS ACTIVITY IN MALE RAT MODEL OF TYPE 2 DIABETES MELLITUS. African Journal of Infectious Diseases, 2025, 19: 54–61.